Publications
- Polatuzumab vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma in the real world2022 | First Faculty of Medicine, Faculty of Medicine in Pilsen, Third Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Diffuse Large B-Cell Lymphoma (DLBCL): Early Patient Management and Emerging Treatment Options2022 | First Faculty of Medicine
- Idelalisib plus rituximab versus ibrutinib in the treatment of relapsed/refractory chronic lymphocytic leukaemia: A real-world analysis from the Chronic Lymphocytic Leukemia Patients Registry (CLLEAR)2023 | First Faculty of Medicine, Third Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Polatuzumab vedotin v léčbě agresivních lymfomů2023 | First Faculty of Medicine
- Cílená terapie u difuzního velkobuněčného B lymfomu2023 | First Faculty of Medicine
- (R)evoluce v léčebných schématech difuzního velkobuněčného B lymfomu?2022 | First Faculty of Medicine
- Expression of molecules of the Wnt pathway and of E-cadherin in the etiopathogenesis of human thymomas2020 | First Faculty of Medicine, Second Faculty of Medicine
Loading network view...